Download PDF
Semin Thromb Hemost 2004; 30(6): 657-664
DOI: 10.1055/s-2004-861508
Copyright © 2004 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Periprocedural Management of Anticoagulation in Patients on Extended Warfarin Therapy

Syed M. Jafri1 , Trupti P. Metha2
  • 1Senior Staff Cardiologist, Department of Cardiology, Henry Ford Hospital, Detroit, Michigan
  • 2Department of Pharmacy, Harper University Hospital/Detroit Medical Center, Detroit, Michigan
Further Information

Publication History

Publication Date:
04 January 2005 (online)

    Permissions and Reprints

ABSTRACT

Patients receiving chronic anticoagulation therapy pose a clinical challenge when therapy needs to be interrupted for surgical or invasive procedures. Maintaining anticoagulation places them at risk of serious bleeding complications, whereas discontinuing anticoagulation puts them at risk of thromboembolic complications. The main patient groups that may require a periprocedural alternative to oral anticoagulation include patients with prosthetic heart valves, atrial fibrillation, and hypercoagulable states and those with chronic venous thrombosis undergoing surgery. Currently, there is little consensus on appropriate perioperative management of patients on long-term warfarin therapy. This article is an attempt to bring together all the available data on periprocedural bridging to assess the available options for patients undergoing surgical procedures and to provide a rationale for using low-molecular-weight heparins (LMWHs) while individualizing the risks versus benefits in a given patient population.

KEYWORDS

Anticoagulants - bridging - warfarin - prosthetic heart valves - hypercoagulability - thrombosis - bleeding

REFERENCES

  • 1 Kearon C, Hirsh J. Management of anticoagulation before and after elective surgery.  N Engl J Med. 1997;  336 1506-1511
    CrossrefPubMedGoogle Scholar
  • 2 Lassen M, Borris L. Prevention in orthopedic surgery and trauma. In: Hull R, Pineo G Disorders of Thrombosis Philadelphia; WB Saunders 1996: 209-216
    Google Scholar
  • 3 Travis S, Wray R, Harrison K. Perioperative anticoagulant control.  Br J Surg. 1989;  76 1107-1108
    PubMedGoogle Scholar
  • 4 Wahl M. Dental surgery in anticoagulated patients.  Arch Intern Med. 1998;  158 1610-1616
    CrossrefPubMedGoogle Scholar
  • 5 Sindet-Pedersen S, Ramstrom G, Bernvil S et al.. Hemostatic effect of tranexamic acid mouthwash in anticoagulant-treated patients undergoing oral surgery.  N Engl J Med. 1989;  320 840-843
    CrossrefPubMedGoogle Scholar
  • 6 Stone L, Kline Jr O, Sklar C. Intraocular lenses and anticoagulation and antiplatelet therapy.  J Am Intraocul Implant Soc . 1985;  11 165-168
    PubMedGoogle Scholar
  • 7 McCormack P, Simcock P, Tullo A. Management of the anticoagulated patient for ophthalmic surgery.  Eye. 1993;  7 749-750
    PubMedGoogle Scholar
  • 8 Hall D, Steen W J, Drummond J et al.. Anticoagulants and cataract surgery.  Ophthalmic Surg. 1988;  19 221-222
    PubMedGoogle Scholar
  • 9 Carter K, Miller K. Phacoemulsification and lens implantation in patients treated with aspirin or warfarin.  J Cataract Refract Surg. 1998;  24 1361-1364
    PubMedGoogle Scholar
  • 10 Narendran N, Williamson T. The effects of aspirin and warfarin therapy on haemorrhage in vitreoretinal surgery.  Acta Ophthalmol Scand. 2003;  81 38-40
    CrossrefPubMedGoogle Scholar
  • 11 Gerson L, Gage B, Owens D et al.. Effect and outcomes of the ASGE guidelines on the periendoscopic management of patients who take anticoagulants.  Am J Gastroenterol. 2000;  95 1717-1724
    CrossrefPubMedGoogle Scholar
  • 12 Van Os E, Kamath P, Gostout C et al.. Gastroenterological procedures among patients with disorders of hemostasis: evaluation and management recommendations.  Gastrointest Endosc. 1999;  50 536-543
    CrossrefPubMedGoogle Scholar
  • 13 Spandorfer J. The management of anticoagulation before and after procedures.  Med Clin North Am. 2001;  85 1109-1116
    CrossrefPubMedGoogle Scholar
  • 14 Dunn A, Turpie A. Perioperative management of patients receiving oral anticoagulants: a systematic review.  Arch Intern Med. 2003;  163 901-908
    CrossrefPubMedGoogle Scholar
  • 15 Stein P, Alpert J, Bussey H et al.. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves.  Chest. 2001;  119 220S-227S
    CrossrefPubMedGoogle Scholar
  • 16 Heit J. Perioperative management of the chronically anticoagulated patient.  J Thromb Thrombolysis. 2001;  12 81-87
    CrossrefPubMedGoogle Scholar
  • 17 Fuster V, Ryden L, Asinger R et al.. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the North American Society of Pacing and Electrophysiology.  J Am Coll Cardiol. 2001;  38 1231-1266
    CrossrefPubMedGoogle Scholar
  • 18 Erkan D, Leibowitz E, Berman J et al.. Perioperative medical management of antiphospholipid syndrome: hospital for special surgery experience, review of literature, and recommendations.  J Rheumatol. 2002;  29 843-849
    PubMedGoogle Scholar
  • 19 Kadayifci A, Haznedaroglu I, Savas M. Risk of withdrawing chronic anticoagulation without antithrombotic prophylaxis.  Am J Gastroenterol. 1997;  92 361-362
    PubMedGoogle Scholar
  • 20 Spandorfer J, Lynch S, Weitz H et al.. Use of enoxaparin for the chronically anticoagulated patient before and after procedures.  Am J Cardiol. 1999;  84 478-480
    CrossrefPubMedGoogle Scholar
  • 21 Galla J, Fuhs B. Outpatient anticoagulation protocol for mechanical valve recipients undergoing non-cardiac surgery.  J Am Coll Cardiol. 2000;  135(Suppl 2) 531A
    PubMedGoogle Scholar
  • 22 Ferreira I, Dos L, Tornos P et al.. Experience with enoxaparin in patients with mechanical heart valves who must withhold acenocumarol.  Heart. 2003;  89 527-530
    CrossrefPubMedGoogle Scholar
  • 23 Tinmouth A, Morrow B, Cruickshank M et al.. Dalteparin as periprocedure anticoagulation for patients on warfarin and at high risk of thrombosis.  Ann Pharmacother. 2001;  35 669-674
    CrossrefPubMedGoogle Scholar
  • 24 Wilson S, Morgan J, Gray L. A model for perioperative outpatient management of anticoagulation in high-risk patients: an evaluation of effectiveness and safety.  Can J Hosp Pharm. 2001;  54 269-277
    PubMedGoogle Scholar
  • 25 Turpie A, Johnson J. Temporary discontinuation of oral anticoagulants: role of low molecular weight heparin (dalteparin).  Can J Cardiol. 2000;  16(Suppl F) 149F
    PubMedGoogle Scholar
  • 26 Johnson J, Turpie A. Temporary discontinuation of oral anticoagulants: role of low molecular weight heparin.  Thromb Haemost. 1999;  82 (Suppl) 62-63 (abst)
    PubMedGoogle Scholar
  • 27 Montalescot G, Polle V, Collet J et al.. Low molecular weight heparin after mechanical heart valve replacement.  Circulation. 2000;  101 1083-1086
    PubMedGoogle Scholar
  • 28 Nutescu E, Helgason C. Outpatient dalteparin peri-procedure bridge therapy in patients maintained on long term warfarin.  Stroke. 2001;  32 328-329 (abst)
    PubMedGoogle Scholar
  • 29 Ansell J, Dalen J, Bussey H et al.. Managing oral anticoagulant therapy.  Chest. 2001;  119(Suppl) 22S-38S
    CrossrefPubMedGoogle Scholar

Syed M JafriM.D. 

Department of Cardiology, Henry Ford Hospital

2799 W. Grand Boulevard, Detroit, MI 48202

Email: sjafri2@hfhs.org

      >